CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Rapamycin inhibited the function of lung CSCs via SOX2

Xie, Li-Xia, Sun, Feng-Feng, He, Bin-Feng, Zhan, Xiao-Feng, Song, Juan, Chen, Sheng-Song, Yu, Shi-Cang, Ye, Xiao-Qun·2016·Tumor Biology
DOI 10.1007/s13277-015-4341-y
Open this paper in CoChat — free account

Abstract

The presence of cancer stem cells (CSCs) is the source of occurrence, aggravation, and recurrence of lung cancer. Accordingly, targeting killing the lung CSCs has been suggested to be an effective approach for lung cancer treatment. In this study, we showed that rapamycin inhibited the mammalian target of rapamycin (mTOR) signal transduction in A549 cells and improved the sensitivity to cisplatin (DDP). The mechanisms involve inhibition of the SOX2 expression, cell proliferation, epithelial-mesenchymal transition (EMT) phenotype, and sphere formation. Interestingly, knocked down SOX2 was a similar effect with rapamycin in A549 sphere. Furthermore, we showed that ectopic expression of Sox2 in A549 cells was sufficient to render them more resistant to rapamycin treatment in vitro. These data suggested that rapamycin inhibited the function of lung CSCs via SOX2. It will be of great interest to further explore the therapeutic strategies of lung cancer.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13277-015-4341-y

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 47

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. · DOI
  2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41. · DOI
  3. Chen DQ, Huang JY, Feng B, Pan BZ, De W, Wang R, et al. Histone deacetylase 1/sp1/microrna-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. PLoS One. 2014;9:e109578. · DOI
  4. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer J Int Cancer. 2011;129:820–31. · DOI
  5. Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor foxm1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res BCR. 2014;16:436. · DOI
  6. Chai S, Tong M, Ng KY, Kwan PS, Chan YP, Fung TM, et al. Regulatory role of mir-142-3p on the functional hepatic cancer stem cell marker cd133. Oncotarget. 2014;5:5725–35. · DOI
  7. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68. · DOI
  8. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of pten/akt/pi3k signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009;106:268–73. · DOI
  9. Kornakiewicz A, Solarek W, Bielecka ZF, Lian F, Szczylik C, Czarnecka AM. Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr Signal Transduct Ther. 2014;8:210–8. · DOI
  10. Laplante M, Sabatini DM. Mtor signaling in growth control and disease. Cell. 2012;149:274–93. · DOI · Paper page
  11. Marinov M, Fischer B, Arcaro A. Targeting mtor signaling in lung cancer. Crit Rev Oncol Hematol. 2007;63:172–82. · DOI
  12. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the pten/mtor/stat3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158–63. · DOI
  13. Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, et al. Antitumor efficacy of the dual pi3k/mtor inhibitor pf-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a mutation. PLoS One. 2013;8:e67258. · DOI
  14. Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, et al. The mtorc1/mtorc2 inhibitor azd2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-Oncology. 2014;16:29–37. · DOI
  15. Dong P, Konno Y, Watari H, Hosaka M, Noguchi M, Sakuragi N. The impact of microrna-mediated pi3k/akt signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med. 2014;12:231. · DOI
  16. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. Sox2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42. · DOI
  17. Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, et al. Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015;8:6287–300.
  18. Yin S, Wang P, Deng W, Zheng H, Hu L, Hurst LD, et al. Dosage compensation on the active x chromosome minimizes transcriptional noise of x-linked genes in mammals. Genome Biol. 2009;10:R74. · DOI
  19. Matsubara S, Ding Q, Miyazaki Y, Kuwahata T, Tsukasa K, Takao S. Mtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep. 2013;3:3230. · DOI
  20. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9. · DOI
  21. Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009;16:1688–703. · DOI
  22. Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014;90:615–21. · DOI
  23. Chan CT, Pang YL, Deng W, Babu IR, Dyavaiah M, Begley TJ, et al. Reprogramming of trna modifications controls the oxidative stress response by codon-biased translation of proteins. Nat Commun. 2012;3:937. · DOI
  24. Xiao Z, Sperl B, Ullrich A, Knyazev P. Metformin and salinomycin as the best combination for the eradication of nsclc monolayer cells and their alveospheres (cancer stem cells) irrespective of egfr, kras, eml4/alk and lkb1 status. Oncotarget. 2014;5:12877–90. · DOI
  25. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141:1728–37. · DOI
  26. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102–13. · DOI
  27. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:7207–16. · DOI
  28. Yin S, Yang J, Lin B, Deng W, Zhang Y, Yi X, et al. Exome sequencing identifies frequent mutation of mll2 in non-small cell lung carcinoma from chinese patients. Sci Rep. 2014;4:6036. · DOI
  29. Dean M. Abc transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009;14:3–9. · DOI
  30. Elliott A, Adams J, Al-Hajj M. The abcs of cancer stem cell drug resistance. IDrugs Investig Drugs J. 2010;13:632–5.
  31. Deng WJ, Nie S, Dai J, Wu JR, Zeng R. Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics MCP. 2010;9:100–16. · DOI
  32. Yin S, Deng W, Zheng H, Zhang Z, Hu L, Kong X. Evidence that the nonsense-mediated mrna decay pathway participates in x chromosome dosage compensation in mammals. Biochem Biophys Res Commun. 2009;383:378–82. · DOI
  33. Yin S, Deng W, Hu L, Kong X. The impact of nucleosome positioning on the organization of replication origins in eukaryotes. Biochem Biophys Res Commun. 2009;385:363–8. · DOI
  34. Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes abc transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like kg-1a cells. Biochem Biophys Res Commun. 2010;394:1098–104. · DOI
  35. Yang C, Zhang Y, Zhang Y, Zhang Z, Peng J, Li Z, Han L, You Q, Chen X, Rao X, Zhu Y, Liao Z. Downregulation of cancer stem cell properties via mtor signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int J Oncol. 2015. · DOI
  36. Engelman JA. Targeting pi3k signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62. · DOI · Paper page
  37. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase b: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344(Pt 2):427–31. · DOI
  38. Zou M, Hu C, You Q, Zhang A, Wang X, Guo Q. Oroxylin a induces autophagy in human malignant glioma cells via the mtor-stat3-notch signaling pathway. Mol Carcinog. 2014. · DOI
  39. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486–98. · DOI
  40. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90. · DOI · Paper page
  41. Chan CT, Deng W, Li F, DeMott MS, Babu IR, Begley TJ, et al. Highly predictive reprogramming of trna modifications is linked to selective expression of codon-biased genes. Chem Res Toxicol. 2015;28:978–88. · DOI
  42. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15. · DOI
  43. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, et al. Epithelial to mesenchymal transition by tgfbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 2011;6:e21548. · DOI
  44. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating abc transporters. Cell Death Dis. 2011;2:e179. · DOI
  45. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. Sox2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511:246–50. · DOI
  46. Hagerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A, et al. Identification of a sox2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-Oncology. 2011;13:1178–91. · DOI
  47. Yang N, Hui L, Wang Y, Yang H, Jiang X. Overexpression of sox2 promotes migration, invasion, and epithelial-mesenchymal transition through the wnt/beta-catenin pathway in laryngeal cancer hep-2 cells. Tumour Biol J Int Soc Oncodevelop Biol Med. 2014;35:7965–73. · DOI

Cited by

Sorted by citations

See all 12

Metadata

Authors
Xie, L.-X., Sun, F.-F., He, B.-F., Zhan, X.-F., Song, J., Chen, S.-S., Yu, S.-C., & Ye, X.-Q.
Venue
Tumor Biology
Publisher
Springer Science and Business Media LLC
Published
2015-11-03
Volume
37
Issue
4
Pages
4929-4937
ISSN
  • 1010-4283
  • 1423-0380
DOI
10.1007/s13277-015-4341-y
Cited by
12
References
1
Language
en
Licence
www.springer.com/tdm (tdm)
Funders
  • National Natural Science Foundation of China (CN) (81160277)
  • Major scientific and technological projects of Jiangxi Province (20143ACB20011)
  • General Project on Social Development by Department of Science and Technology of Jiang Xi Province (20141BBG70035)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapamycin inhibited the function of lung CSCs via SOX2. https://app.cochat.ai/papers/10.1007/s13277-015-4341-y
The paper
Xie, L.-X., Sun, F.-F., He, B.-F., Zhan, X.-F., Song, J., Chen, S.-S., Yu, S.-C., & Ye, X.-Q. (2016). Rapamycin inhibited the function of lung CSCs via SOX2. Tumor Biology. https://doi.org/10.1007/s13277-015-4341-y